MorphoSys Presents Multiple Analyses of the MANIFEST Phase 2

New translational data suggests potential disease-modifying effects following treatment with pelabresib of both first-line and ruxolitinib-relapsed/refractory patients A comparative model suggests

Related Keywords

Germany , New York , United States , Boston , Massachusetts , Vienna , Wien , Austria , Planegg , Bayern , Thomas Biegi , Julia Neugebauer , John Mascarenhas , Eamonn Nolan , Myles Clouston , Development Officer , Linkedin , Adult Leukemia Program , Twitter , European Hematology Association , Constellation Pharmaceuticals Inc , Tisch Cancer Institute At Mount Sinai , Nasdaq , Exchange Commission , Hybrid Congress , Tisch Cancer Institute , Mount Sinai , Malte Peters , Morphosys Chief Research , Morphosy Annual Report , Morphosys , Presents , Multiple , Analyses , Manifest , Hase , Trial , Nvestigating , Potential , Pelabresib , Treatment , Myelofibrosis , 022 ,